Compare Crispr Therapeutics AG (CRSP) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs United Parcel Service Inc — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while United Parcel Service Inc trades at $113.36 (market cap $96.62B). The key difference: United Parcel Service Inc is far larger — about 19.4× Crispr Therapeutics AG's market cap, and United Parcel Service Inc pays a 5.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | UPS | |
|---|---|---|
Market Cap | $4.97B | $96.62B |
Sector | Health | Industrials |
52-Week High | $76.78 | $120.00 |
52-Week Low | $44.34 | $82.58 |
Enterprise Value | $3.32B | $119.48B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
UPS stock trades at $112.89, up 0.37% today, with a bullish technical signal and consistent earnings beats. The company maintains solid profitability with a 5.94% net margin and 33.41% ROE, though revenue has declined from $100.3B in 2022 to $88.66B in 2025. Recent news highlights a $48 million investment in healthcare logistics and AI-driven efficiency improvements, while analyst sentiment is mixed with a consensus price target of $112.
The outlook for UPS is balanced; cost controls and strategic investments support margins, but revenue pressure and competitive threats from Amazon pose risks. The stock's valuation at a P/E of 18.27 is reasonable, yet growth headwinds and dividend sustainability concerns warrant caution. Upside depends on execution in logistics innovation and reversing top-line declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
